Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis.
The antiplatelet drug ticlopidine was assessed as an agent for improving the patency of Brescia-Cimino arteriovenous fistulas as access for hemodialysis. In a double-blind randomized study over 1 month, two of six fistulas in the ticlopidine group and five of nine in the placebo group failed. A further one placebo and two ticlopidine patients still had functioning fistulas at the time of withdrawal for technical reasons from the trial. Ticlopidine appears, therefore, to enhance the efficacy of Brescia-Cimino fistulas, at least in the short term.
D000925:Anticoagulants / Q000627:therapeutic use*; D001166:Arteriovenous Shunt, Surgical; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006083:Graft Occlusion, Vascular / Q000517:prevention & control*; D006801:Humans; D006435:Renal Dialysis / Q000379:methods*; D013876:Thiophenes / Q000627:therapeutic use*; D013927:Thrombosis / Q000517:prevention & control; D013988:Ticlopidine
D000925:Anticoagulants; D013876:Thiophenes; D013988:Ticlopidine